Video Wednesday

Why It Matters

The robot introduces unprecedented multi‑arm capability, potentially reshaping surgical workflows and accelerating adoption of robotic assistance across specialties.

Key Takeaways

• OTTAVA features six articulated arms for complex procedures
• Joint venture between Verb Robotics and Johnson & Johnson
• Designed for minimally invasive surgeries and precision tasks
• Modular design enables rapid reconfiguration across specialties
• Expected to reduce operation time and improve patient outcomes

Pulse Analysis

The surgical robotics market has been dominated by single‑arm platforms that excel at precision but often require auxiliary instruments or manual assistance. As hospitals seek to increase operating room efficiency, manufacturers are exploring multi‑arm configurations that can perform parallel tasks, reduce instrument exchanges, and improve ergonomics for surgeons. OTTAVA arrives at a time when demand for higher throughput and lower complication rates is driving investment in next‑generation robotic solutions.

OTTAVA’s six‑arm design distinguishes it from competitors by offering simultaneous manipulation of multiple tissues or devices. Built on Verb’s modular chassis, each arm can be swapped or repositioned to suit specific procedural requirements, enabling a single system to serve orthopedics, neurosurgery, and interventional cardiology. Integration with Johnson & Johnson’s imaging and instrument ecosystem ensures seamless data flow and real‑time feedback, while the robot’s control software leverages AI‑assisted motion planning to enhance accuracy and reduce surgeon fatigue.

If OTTAVA achieves regulatory clearance, its impact could extend beyond clinical outcomes to the economics of care. Shorter procedure times translate to higher case volumes per day, improving hospital revenue streams and potentially lowering per‑procedure costs. Moreover, the robot’s versatility may accelerate adoption in midsize hospitals that previously could not justify a single‑purpose system. As insurers and providers evaluate value‑based care models, technologies that combine clinical efficacy with cost efficiency, like OTTAVA, are poised to become central to the future of surgical practice.